In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 6.36 below Maxcyte Inc average.

Within Medical Laboratories industry 4 other companies have achieved higher Quick Ratio than Maxcyte Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 275 to 430.

Explain Quick Ratio?
How much Cash & cash equivalents MXCT�s has?
What are MXCT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MXCT/financial-strength

https://api.csimarket.com/api/v1/companies/MXCT/fundamentals

https://api.csimarket.com/api/v1/companies/MXCT/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

MXCT Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	7.63 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-4.21 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	6.36	Subscribe	Subscribe	Subscribe	Subscribe
MXCT's Total Ranking	# 430	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	60.85 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-4.17 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 5
Healthcare Sector	# 151
Overall Market	# 430

Quick Ratio Statistics
High	Average	Low
21.32	12.35	5.98
(Sep 30 2021)		(Dec 31 2020)

Financial Statements
Maxcyte Inc 's Current Liabilities	$ 16 Millions	Visit MXCT's Balance sheet
Maxcyte Inc 's Cash & cash equivalent	$ 101 Millions	Visit MXCT's Balance sheet
Source of MXCT's Sales		Visit MXCT's Sales by Geography

Cumulative Maxcyte Inc 's Quick Ratio

MXCT's Quick Ratio for the trailling 12 Months

MXCT Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-7.67 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-20.6 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	8.78	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3917	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	2.43 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-1.06 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to MXCT Financial Strength Comparisons >> Go to Compare MXCT Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q3 2026 to $15.92 millions, cumulative Quick Ratio decreased to 8.78 above the MXCT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 34 other companies have achieved higher Quick Ratio than Maxcyte Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2746 to 3917.

Explain Quick Ratio?
How much Cash & cash equivalents MXCT�s has?
What are MXCT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 35
Healthcare Sector	# 890
Within the Market	# 3917

trailing twelve months Quick Ratio Statistics
High	Average	Low
7.37	3.15	1.2
(Jun 30 2022)		(Mar 31 2026)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Medical Laboratories Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Aclarion Inc	13.58	$ 14.188 Millions	$ 1.044 Millions
Celcuity Inc	12.38	$ 642.703 Millions	$ 51.925 Millions
Miragen Therapeutics Inc	11.70	$ 955.206 Millions	$ 81.673 Millions
Billiontoone Inc	9.26	$ 561.512 Millions	$ 60.637 Millions
Maxcyte inc	6.36	$ 101.280 Millions	$ 15.916 Millions
Personalis Inc	5.17	$ 254.841 Millions	$ 49.274 Millions
Veracyte Inc	4.40	$ 370.532 Millions	$ 84.209 Millions
Castle Biosciences Inc	4.11	$ 277.665 Millions	$ 67.612 Millions
Fulgent Genetics Inc	4.07	$ 292.739 Millions	$ 71.877 Millions
Omniab Inc	3.81	$ 64.210 Millions	$ 16.853 Millions
Guardant Health Inc	2.75	$ 1,026.848 Millions	$ 373.165 Millions
Incyte Corporation	2.68	$ 3,854.572 Millions	$ 1,437.818 Millions
Exagen Inc	2.14	$ 28.092 Millions	$ 13.100 Millions
Biodesix Inc	1.99	$ 28.409 Millions	$ 14.248 Millions
Caredx Inc	1.80	$ 250.480 Millions	$ 138.975 Millions
Butterfly Network Inc	1.80	$ 122.301 Millions	$ 67.987 Millions
Sera Prognostics Inc	1.80	$ 44.089 Millions	$ 24.527 Millions

Date modified: 2026-11-11T13:53:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.